

BOSTON SCIENTIFIC CORP  
Form 8-K  
March 03, 2006

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(D) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): **March 3, 2006**

**BOSTON SCIENTIFIC CORPORATION**

(Exact Name of Registrant as Specified in Its Charter)

|   |  |                          |  |
|---|--|--------------------------|--|
| <b>Delaware</b>   |  | <b>001-11083</b>         | <b>04-2695240</b>                          |
| (State or Other Jurisdiction of<br>Incorporation)         |  | (Commission File Number) | (I.R.S. Employer Identification<br>Number) |
|   |  |                          |  |
| <b>One Boston Scientific Place, Natick, Massachusetts</b> |  |                          | <b>01760-1537</b>                          |
| (Address of Principal Executive Offices)                  |  |                          | (Zip Code)                                 |

Registrant's Telephone Number, Including Area Code: **(508) 650-8000**

Edgar Filing: BOSTON SCIENTIFIC CORP - Form 8-K

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
  - o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
  - o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
  - o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01. Other Events**

Language was inadvertently left out of the last sentence in the paragraph entitled "Endoscopic Video Imaging" on page 10 of Boston Scientific's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 1, 2006. The sentence should read as follows: "We expect to conduct first-in-man trials of the Endovations System in the second quarter of 2006 and to launch commercially in the U.S. in 2007."

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BOSTON SCIENTIFIC CORPORATION

By: /s/ Lawrence J. Knopf  
Name: Lawrence J. Knopf  
Title: Vice President and Assistant General Counsel

Dated: March 3, 2006